See more : Sinopec Kantons Holdings Limited (0934.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Elekta AB (publ) (EKTAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elekta AB (publ), a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- PTC India Limited (PTC.BO) Income Statement Analysis – Financial Results
- Takachiho Co.,Ltd. (8225.T) Income Statement Analysis – Financial Results
- Wheeler Real Estate Investment Trust, Inc. (WHLR) Income Statement Analysis – Financial Results
- PT Bank Central Asia Tbk (PBCRF) Income Statement Analysis – Financial Results
- Bright Outdoor Media Limited (BRIGHT.BO) Income Statement Analysis – Financial Results
Elekta AB (publ) (EKTAY)
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.12B | 16.87B | 14.55B | 13.76B | 14.60B | 13.56B | 11.33B | 10.70B | 11.22B | 10.84B | 10.69B | 10.34B | 9.05B | 7.90B | 7.39B | 6.69B | 5.08B | 4.53B | 4.42B | 3.15B | 2.90B | 2.78B | 2.74B |
| Cost of Revenue | 11.32B | 10.52B | 9.11B | 8.15B | 8.46B | 7.88B | 6.58B | 6.28B | 6.61B | 6.53B | 6.05B | 5.56B | 4.83B | 4.24B | 3.99B | 3.66B | 2.90B | 2.58B | 2.52B | 1.90B | 1.78B | 1.76B | 1.70B |
| Gross Profit | 6.80B | 6.35B | 5.44B | 5.61B | 6.14B | 5.68B | 4.75B | 4.43B | 4.61B | 4.31B | 4.65B | 4.78B | 4.22B | 3.67B | 3.41B | 3.03B | 2.18B | 1.94B | 1.90B | 1.25B | 1.12B | 1.02B | 1.04B |
| Gross Profit Ratio | 37.55% | 37.64% | 37.37% | 40.76% | 42.03% | 41.90% | 41.90% | 41.36% | 41.11% | 39.73% | 43.45% | 46.25% | 46.61% | 46.39% | 46.08% | 45.31% | 42.94% | 42.92% | 43.02% | 39.66% | 38.52% | 36.79% | 37.98% |
| Research & Development | 1.95B | 1.42B | 1.37B | 1.49B | 1.66B | 1.59B | 1.10B | 1.02B | 1.07B | 952.00M | 866.00M | 715.00M | 604.00M | 552.00M | 535.00M | 485.00M | 383.00M | 332.00M | 293.00M | 208.00M | 218.00M | 148.00M | 144.00M |
| General & Administrative | 1.37B | 1.40B | 1.17B | 1.09B | 1.09B | 1.04B | 948.00M | 928.00M | 1.03B | 1.05B | 918.00M | 878.00M | 754.00M | 749.00M | 708.00M | 642.00M | 498.00M | -190.00M | -210.00M | -120.00M | 291.00M | 285.00M | 315.00M |
| Selling & Marketing | 1.64B | 1.60B | 1.36B | 1.14B | 1.44B | 1.30B | 1.21B | 1.17B | 1.34B | 1.34B | 1.06B | 1.15B | 1.08B | 957.00M | 970.00M | 933.00M | 679.00M | 595.00M | 580.00M | 395.00M | 375.00M | 356.00M | 367.00M |
| SG&A | 3.01B | 3.00B | 2.53B | 2.23B | 2.54B | 2.34B | 2.16B | 2.09B | 2.36B | 2.38B | 1.97B | 2.03B | 1.84B | 1.71B | 1.68B | 1.58B | 1.18B | 405.00M | 370.00M | 275.00M | 666.00M | 641.00M | 682.00M |
| Other Expenses | -194.00M | 0.00 | 48.00M | 85.00M | -11.00M | -23.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 141.00M | 4.00M | -34.00M | -30.00M | -14.00M | -46.00M | -67.00M | 24.00M |
| Operating Expenses | 4.76B | 4.48B | 3.95B | 3.80B | 4.18B | 3.90B | 3.25B | 3.11B | 3.43B | 3.34B | 2.84B | 2.74B | 2.44B | 2.26B | 2.21B | 2.20B | 1.56B | 1.54B | 1.34B | 1.11B | 838.00M | 722.00M | 850.00M |
| Cost & Expenses | 16.08B | 15.00B | 13.06B | 11.95B | 12.65B | 11.78B | 9.84B | 9.39B | 10.04B | 9.87B | 8.89B | 8.30B | 7.27B | 6.50B | 6.20B | 5.86B | 4.46B | 4.12B | 3.86B | 3.01B | 2.62B | 2.48B | 2.55B |
| Interest Income | 108.00M | 78.00M | 42.00M | 29.00M | 63.00M | 65.00M | 66.00M | 31.00M | 37.00M | 25.00M | 22.00M | 32.00M | 45.00M | 26.00M | 6.00M | 23.00M | 108.00M | 46.00M | 28.00M | 22.00M | 43.00M | 37.00M | 36.00M |
| Interest Expense | 482.00M | 226.00M | 148.00M | 233.00M | 214.00M | 156.00M | 163.00M | 209.00M | 240.00M | 217.00M | 202.00M | 223.00M | 200.00M | 58.00M | 50.00M | 107.00M | 76.00M | 71.00M | 59.00M | 15.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.14B | 1.06B | 1.04B | 1.20B | 1.26B | 943.00M | 675.00M | 655.00M | 634.00M | 512.00M | 414.00M | 349.00M | 295.00M | 241.00M | 229.00M | 208.00M | 176.00M | 136.00M | 171.00M | 81.00M | 88.00M | 72.00M | 63.00M |
| EBITDA | 3.29B | 2.57B | 2.69B | 3.07B | 2.94B | 2.68B | 2.23B | 1.20B | 1.06B | 1.45B | 2.12B | 2.34B | 2.20B | 1.76B | 1.47B | 1.09B | 794.00M | 714.00M | 674.00M | 474.00M | 367.00M | 373.00M | 253.00M |
| EBITDA Ratio | 18.14% | 14.74% | 18.48% | 22.28% | 20.16% | 19.80% | 19.64% | 16.09% | 14.80% | 13.36% | 21.31% | 23.39% | 24.22% | 22.31% | 19.90% | 16.28% | 15.63% | 15.78% | 15.25% | 15.04% | 12.66% | 13.41% | 9.24% |
| Operating Income | 2.04B | 1.43B | 1.64B | 1.91B | 1.66B | 1.70B | 1.54B | 598.00M | 423.00M | 937.00M | 1.73B | 2.01B | 1.85B | 1.50B | 1.23B | 830.00M | 650.00M | 509.00M | 453.00M | 364.00M | 306.00M | 323.00M | 207.00M |
| Operating Income Ratio | 11.25% | 8.48% | 11.29% | 13.85% | 11.35% | 12.51% | 13.57% | 5.59% | 3.77% | 8.64% | 16.15% | 19.46% | 20.44% | 19.00% | 16.67% | 12.41% | 12.79% | 11.25% | 10.25% | 11.55% | 10.55% | 11.61% | 7.56% |
| Total Other Income/Expenses | -371.00M | -233.00M | -142.00M | -276.00M | -203.00M | -116.00M | -164.00M | -258.00M | -234.00M | -221.00M | -225.00M | -242.00M | -141.00M | -38.00M | -40.00M | -56.00M | -26.00M | -2.00M | -9.00M | 14.00M | 19.00M | -6.00M | 14.00M |
| Income Before Tax | 1.67B | 1.20B | 1.50B | 1.63B | 1.45B | 1.58B | 1.37B | 340.00M | 189.00M | 716.00M | 1.50B | 1.80B | 1.71B | 1.46B | 1.19B | 774.00M | 624.00M | 507.00M | 444.00M | 378.00M | 325.00M | 317.00M | 221.00M |
| Income Before Tax Ratio | 9.21% | 7.10% | 10.32% | 11.84% | 9.96% | 11.66% | 12.12% | 3.18% | 1.68% | 6.61% | 14.05% | 17.41% | 18.88% | 18.52% | 16.13% | 11.57% | 12.28% | 11.20% | 10.04% | 11.99% | 11.21% | 11.40% | 8.07% |
| Income Tax Expense | 365.00M | 254.00M | 345.00M | 377.00M | 370.00M | 382.00M | 276.00M | 214.00M | 44.00M | 158.00M | 350.00M | 449.00M | 480.00M | 433.00M | 359.00M | 228.00M | 218.00M | 161.00M | 140.00M | 125.00M | -77.00M | -88.00M | -78.00M |
| Net Income | 1.30B | 943.00M | 1.15B | 1.25B | 1.08B | 1.20B | 1.10B | 125.00M | 137.00M | 552.00M | 1.15B | 1.34B | 1.23B | 1.03B | 833.00M | 546.00M | 406.00M | 348.00M | 304.00M | 253.00M | 248.00M | 234.00M | 145.00M |
| Net Income Ratio | 7.19% | 5.59% | 7.93% | 9.11% | 7.42% | 8.84% | 9.70% | 1.17% | 1.22% | 5.09% | 10.73% | 12.96% | 13.56% | 13.04% | 11.27% | 8.16% | 7.99% | 7.69% | 6.88% | 8.03% | 8.55% | 8.41% | 5.30% |
| EPS | 3.41 | 2.47 | 3.02 | 3.28 | 2.84 | 3.14 | 2.88 | 0.33 | 0.36 | 1.45 | 3.01 | 3.52 | 3.26 | 2.76 | 2.26 | 1.48 | 1.10 | 0.93 | 0.81 | 0.67 | 0.63 | 0.61 | 0.39 |
| EPS Diluted | 3.41 | 2.47 | 3.02 | 3.28 | 2.84 | 3.14 | 2.88 | 0.33 | 0.36 | 1.45 | 2.87 | 3.52 | 3.23 | 2.73 | 2.24 | 1.48 | 1.10 | 0.92 | 0.80 | 0.67 | 0.63 | 0.60 | 0.37 |
| Weighted Avg Shares Out | 382.08M | 382.08M | 382.08M | 382.08M | 382.08M | 382.03M | 382.03M | 381.31M | 381.29M | 381.29M | 381.28M | 380.67M | 376.43M | 373.36M | 368.83M | 368.12M | 368.80M | 374.79M | 376.54M | 375.96M | 391.02M | 384.23M | 372.58M |
| Weighted Avg Shares Out (Dil) | 382.09M | 382.37M | 382.08M | 382.08M | 382.08M | 382.03M | 382.03M | 381.31M | 381.29M | 381.29M | 400.69M | 380.67M | 380.13M | 378.03M | 371.78M | 368.12M | 369.92M | 377.00M | 379.12M | 376.73M | 391.02M | 392.33M | 390.05M |
Are Investors Undervaluing Elekta (EKTAY) Right Now?
Elekta AB (publ) (EKTAF) Q3 2024 Earnings Call Transcript
Is Elekta (EKTAY) Stock Undervalued Right Now?
Is Elekta (EKTAY) a Great Value Stock Right Now?
Elekta AB (EKTAF) Q2 2024 Earnings Call Transcript
ZAP Surgical Deals Two More Blows to Elekta in IP Suit, Removing Barriers to Mass Adoption of the ZAP-X Radiosurgery Platform
Elekta AB (publ) (EKTAF) Q1 2024 Earnings Call Transcript
Elekta AB (publ) (EKTAF) Q3 2023 Earnings Call Transcript
Elekta AB (publ) (EKTAF) Q2 2023 Earnings Call Transcript
Elekta AB (publ) (EKTAF) Q1 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports